InnoCare Pharma Ltd.(INCPF)
$1.51+0.01 (+0.67%)
INCPF
InnoCare Pharma Ltd. stock forecast
$1.51
At close:+0.01 (+0.67%)
InnoCare Pharma Ltd. (INCPF) Stock Forecast & Price Target
2 Followers
INCPF Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to InnoCare Pharma Ltd. in the past 3 months
INCPF Stock 12 Month Forecast
Average Price Target
$2.43▲(61.56% Upside)Based on 6 Wall Street analysts offering 12 month price targets for InnoCare Pharma Ltd. in the last 3 months. The average price target is $2.43 with a high forecast of $2.81 and a low forecast of $2.17. The average price target represents a 61.56% change from the last price of $1.51.
Past 12 Months12 Month ForecastJan2026Oct2026
High$2.81
Average$2.43
Low$2.17
Highest Price TargetHighest$2.81Average Price Target$2.43Lowest Price TargetLowest$2.17
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Mark Kong CFA | DBS | $2.33 | buy | 55.08%Upside | Reiterated | 11/09/26 | ||
| Jill Wu | CMB International Securities | $2.34→$2.41 | buy | 60.17%Upside | Reiterated | 10/28/26 | ||
 Unknown AnalystNot Ranked | Guotai Haitong | $2.46 | buy | 63.64%Upside | Reiterated | 10/22/26 | ||
| Unknown AnalystNot Ranked | SDIC Securities | $2.41 | buy | 60.00%Upside | Reiterated | 08/26/26 | ||
| Unknown AnalystNot Ranked | CICC | $2.81 | buy | 86.44%Upside | Reiterated | 08/25/26 | ||
| Jack Lin | Morgan Stanley | $2.17 | buy | 44.06%Upside | Reiterated | 08/25/26 | ||
| Unknown AnalystNot Ranked | UBS | $2.73 | buy | 81.35%Upside | Reiterated | 07/15/26 | ||
| Unknown AnalystNot Ranked | Shenwan Hongyuan | $2.47 | buy | 64.40%Upside | Reiterated | 05/13/26 | ||
| Unknown AnalystNot Ranked | Guoyuan Securities (HK) | $2.14 | buy | 42.45%Upside | Reiterated | 12/24/25 | ||
| Unknown AnalystNot Ranked | SWS Res | $2.42 | buy | 61.01%Upside | Reiterated | 11/17/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Mark Kong CFADBS | BuyReiterated$2.33 | 11/09/26 | 55.08%Upside | ||
| Jill WuCMB International Securities | BuyReiterated$2.34→$2.41 | 10/28/26 | 60.17%Upside | ||
| Unknown AnalystGuotai HaitongNot Ranked | BuyReiterated$2.46 | 10/22/26 | 63.64%Upside | ||
| Unknown AnalystSDIC SecuritiesNot Ranked | BuyReiterated$2.41 | 08/26/26 | 60.00%Upside | ||
| Unknown AnalystCICCNot Ranked | BuyReiterated$2.81 | 08/25/26 | 86.44%Upside | ||
| Jack LinMorgan Stanley | BuyReiterated$2.17 | 08/25/26 | 44.06%Upside | ||
| Unknown AnalystUBSNot Ranked | BuyReiterated$2.73 | 07/15/26 | 81.35%Upside | ||
| Unknown AnalystShenwan HongyuanNot Ranked | BuyReiterated$2.47 | 05/13/26 | 64.40%Upside | ||
| Unknown AnalystGuoyuan Securities (HK)Not Ranked | BuyReiterated$2.14 | 12/24/25 | 42.45%Upside | ||
| Unknown AnalystSWS ResNot Ranked | BuyReiterated$2.42 | 11/17/25 | 61.01%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering InnoCare Pharma Ltd.
3 Months
Success Rate3/5 ratings generated profit
60%
Average Return
+36.96%
Copying Jill Wu's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +36.96% per trade.
1 Year
Success Rate3/5 ratings generated profit
60%
Average Return
+19.56%
Copying Jill Wu's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +19.56% per trade.
2 Years
Success Rate4/5 ratings generated profit
80%
Average Return
+55.76%
Copying Jill Wu's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +55.76% per trade.
INCPF Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 3 | 4 |
| Buy | 2 | 4 | 4 | 3 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 3 | 4 | 4 | 6 | 4 |
In the current month, INCPF has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INCPF average Analyst price target in the past 3 months is 2.43.
INCPF Financial Forecast
High$0.04
Consensus$0.04
Low$0.03
INCPF Earnings Forecast
Next quarter’s earnings estimate for INCPF is $0.04 with a range of $0.03 to $0.04. The previous quarter’s EPS was $0.04. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$257M
Consensus$249M
Low$242M
INCPF Sales Forecast
Next quarter’s sales forecast for INCPF is $249.27M with a range of $241.61M to $256.93M. The previous quarter’s sales results were $142.66M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
INCPF Stock Forecast FAQ
What is INCPF’s average 12-month price target, according to analysts?
Based on analyst ratings, InnoCare Pharma Ltd.’s 12-month average price target is $2.43.
What is INCPF’s upside potential, based on the analysts’ average price target?
InnoCare Pharma Ltd. has 61.56% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INCPF a Buy, Sell or Hold?
InnoCare Pharma Ltd. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is InnoCare Pharma Ltd.’s price target?
The average price target for InnoCare Pharma Ltd. is $2.43. This is based on 6 12-month price targets, issued in the past 3 months. The highest analyst price target is $2.81, the lowest forecast is $2.17. The average price target represents a 61.56% increase from the current price of $1.505.
What do analysts say about InnoCare Pharma Ltd.?
InnoCare Pharma Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of INCPF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
